ATP measurement

152
A luminescent ATP detection assay kit was used to determine the total levels of cellular 153 ATP as per manufacturer's instructions (abcam, Cat #ab113849). Briefly, long-term co-154 cultures were either treated with 125 nM of PP or left untreated followed by isolation of 155 the different cell populations, as described above. 20,000 of the isolated cells were then 156 lysed and added into the detection solution and the luminescence was measured using a 157 BioTek plate reader.
158 Mitochondrial staining assay
159
Leukemic cell populations were isolated from long-term co-culture as described above. 231 Furthermore, hexokinase II (HK2) was found to be the most significantly over-expressed 232 in the PD cell population in all the four independent co-cultures that were used for the 233 gene expression analysis ( 242 Co-culture affects activity of mitochondrial complexes
243
To validate the observations derived from the gene expression analysis, we assayed 244 the enzymatic activity of the mitochondrial complexes in two ALL cell lines (REH and 245 SUPB15) using cell lysates from M, S and PD cells. Complex I activity of the S and PD 246 cells was significantly reduced when compared to M cells for the REH ALL cell line; while 247 it was low but unchanged in all three populations of the SUPB15 cells ( Fig. 2A) .
248 Specifically, Complex I activity was decreased by 58 % in S cells and by 55 % in the PD 249 cells as compared to M cells. Interestingly, for SUPB15 cells, the PD cells showed 250 significant reduction in Complex III activity compared to M and S cells (Fig. 2B) .
12
251 Furthermore, Complex IV and Complex V showed no significant differences in activity 252 between the three cell populations in either REH or SUPB15 cells ( Fig. 2C and D) .
Leukemic cells in co-culture have dysfunctional mitochondrial bioenergetics
254
To understand how the decreased ETC complex activity of the leukemic cells in co-255 culture affects the mitochondrial bioenergetics, we looked at ATP production and the 256 relative mitochondrial mass within the different sub-populations of leukemic cells in co-257 culture. We found that the ATP production was significantly decreased in both REH and 258 SUPB15 cells in co-culture with BMSC when compared to the M cells ( Fig. 3A and B) . (Fig. 4A) . The IC50 of 273 PP ranged from 0.17 M for REH cells to 1 M for RS4 cells (Fig. 4B) . To determine the 13 274 effect of PP on the cell cycle, we treated REH and SUPB15 cells with PP and observed 275 a significant decrease in the number of cells in the S and M phases of the cell cycle 276 ( Fig. S3A and B) . Subsequently, we wanted to evaluate the effects of PP on leukemic 277 cells when they were co-cultured with BMSC. Treatment with PP resulted in a decrease 278 in the total number of live cells in both REH and TOM1 cell lines, irrespective of cell culture 279 conditions ( Fig. 4C and E) . This overall decrease in the total number of live cells was 280 accompanied by a significant decrease in cell viability. Specifically, in REH cells, a ~55%
281 decreased viability in M and S cell populations was observed compared to ~80 % in the 282 PD cell population (Fig. 4D) . A similar pattern was observed in TOM1 cells treated with 283 PP, with a ~75% decreased viability in M and S cell population compared to ~97% viability 284 in the PD cell population (Fig. 4F ).
Pyrvinium pamoate nanoparticles (NP [PP]) demonstrate anti-leukemic activity
286
Since PP has poor bioavailability, we encapsulated it within nanoparticles composed 287 of PGLA and PEG complexes. We first determined if the nanoparticles (NP) by 288 themselves had any activity on the bone marrow stromal components or the ALL cells. 294 (PBMC). However, it did cause a significant decrease in cell proliferation (46 %) when 295 exposed to a B lymphoblastoid cell, SD1 (Fig. 5B) . To ascertain that the differential effects 296 of PP between the normal and the leukemic cells was not due to differences in cell 14 297 proliferation rate, we utilized normal primary CD3+ cells and induced proliferation using a
CD3/CD28 T cell activator. Treatment of dormant or proliferating T cells with PP did not
299 result in decreased cell viability in the dormant T cell population and showed a minimal 300 decrease in viability (~13 %) in the proliferating T cells (Fig. S4) . Finally, we wanted to 301 determine the anti-leukemic effects of the PP encapsulated NP in a hemosphere assay.
302 We utilized SD1 cells to form hemospheres for 4 days, after which they were treated with 303 250 nM of the PP encapsulated NP. After 48 hrs of treatment, the NP were able to 304 penetrate the pre-formed spheres resulting in a loss of hemospheres (Fig. 5C ).
305 Quantitation of the spheres using light microscopy showed that the PP encapsulated 306 nanoparticles resulted in a loss of spheres and were efficient in inhibiting the sphere-307 forming abilities of SD1 cells, to the point no spheres formed after treatment (Fig. 5C ).
Pyrvinium pamoate encapsulated nanoparticles inhibit mitochondrial respiration
309
To understand the mechanism of the PP-induced cell death in ALL cells, we analyzed 310 its effect on ATP production. As seen in Fig. 6A 326 PP and rotenone induced an additive 40% cell death (Fig. 6F) .
Discussion
328
In the present study, we have utilized an in vitro co-culture system to characterize PD 329 drug-resistant leukemic cells that mimic the cell population that constitutes minimal 330 residual disease found within the BM of relapsed ALL patients. We have shown that the 331 gene expression profile of proteins involved in the mitochondrial ETC complex is 332 downregulated in PD cells, with a significant reduction in Complex I activity, and that 333 mitochondrial dysfunction was accompanied by a reduction in mitochondrial mass and 334 reduced ATP production in PD cells. PP inhibits mitochondrial bioenergetics and induces 335 cell death in a variety of ALL cell lines and importantly is also able to specifically target 336 the resistant PD cells for death. Looking ahead toward possible use in the clinic, we also 337 showed that PP encapsulation in nanoparticles to potentially increase its bioavailability 338 does not diminish the activity of PP and opens up an avenue to increase its systemic 339 availability. The complete mechanism of PP-mediated leukemic cell death includes its 340 ability to inhibit ATP production in addition to its mitochondrial inhibitory activity. Taken 341 together, this report demonstrates the potential for the use of PP as an anti-leukemic 342 agent, especially in treatment of patients with relapsed refractory disease.
343
We had previously reported that the drug resistant ALL cell sub-population designated 
381
We had previously shown, using a Seahorse metabolic assay, that rotenone induced 382 a complete inhibition of oxygen consumption rate in ALL cells [10] . In our study, 383 pretreatment of ALL cells with rotenone did not abolish the anti-leukemic activity of PP.
384 In fact, the combination of rotenone and PP gave an additive cell death activity indicating 385 a second mechanism of action for inducing death in ALL cells by PP. Our lab had 386 previously reported the importance of -catenin signaling in not only maintaining the stem 387 cell profile of leukemic stem cells but also in providing proliferative cues that are critical 388 for survival within the BM microenvironment [37, 38] . At the same time, PP has been
